Alfuzosin Hydrochloride
Product Images NDC 55648-738

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 55648-738). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Wockhardt Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (Alfuzosintablets M Figure 01)

Label (Alfuzosintablets M Figure 01)
Each tablet contains 10mg of Alfuzosin hydrochloride, USP. The usual dosage can be found in the package insert. These are extended-release tablets that should be protected from light and moisture, dispensed in a tight and light-resistant container per the USP. They should be stored at room temperature and kept out of reach of children. The manufacturer is Wockhardt Limited, located in Mumbai, India.*
FDA Label Image

Label (Alfuzosintablets M Figure 02)

Label (Alfuzosintablets M Figure 02)
Each tablet of this drug contains 10 mg of Alfuzosin Hydrochloride, USP, which is used to treat symptoms of enlarged prostate in men. The usual dosage information is provided in the package insert. The drug should be protected from light and moisture, and stored at room temperature. This is a prescription medication and should be dispensed by a licensed pharmacist. The drug comes in a pack of 500 tablets and caution must be taken to keep it out of reach of children.*
FDA Label Image

Structure (Alfuzosintablets M Figure 03)

Structure (Alfuzosintablets M Figure 03)
FDA Label Image

Figure 1 (Alfuzosintablets M Figure 04)

Figure 1 (Alfuzosintablets M Figure 04)
FDA Label Image

Figure 2 (Alfuzosintablets M Figure 05)

Figure 2 (Alfuzosintablets M Figure 05)
FDA Label Image

Figure 3 (Alfuzosintablets M Figure 06)

Figure 3 (Alfuzosintablets M Figure 06)
FDA Label Image

Figure 4 (Alfuzosintablets M Figure 07)

Figure 4 (Alfuzosintablets M Figure 07)
FDA Label Image

Figure 5 (Alfuzosintablets M Figure 08)

Figure 5 (Alfuzosintablets M Figure 08)
FDA Label Image

Figure 6 (Alfuzosintablets M Figure 09)

Figure 6 (Alfuzosintablets M Figure 09)
This appears to be a list of two items, with the first item being "PLACEEO" and having a count of 147. The second item appears to be related to pharmaceuticals and references "Alfuzosin HCI extended-release tablets" with a count of 136.*
FDA Label Image

Figure 7 (Alfuzosintablets M Figure 10)

Figure 7 (Alfuzosintablets M Figure 10)
This text describes a clinical trial involving the use of a placebo (N=150) and Alluzosin HCl extended-release tablets (N=151). The text includes a graph tracking treatment progress over the course of 84 days, and it notes that there was no statistically significant difference between the two groups (NS p>0.08).*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.